Product Certification&
    Enterprise Certification

  • Mr.John
    Tel: +86-371-86658258

  • Ms.cara
    sales
    Tel: +86-371-86652073

  • Ms.candice
    sales Manager
    Tel:  +86-371-86658258

  • Ms.Joy
    sales
    Tel: +86-371-56057376

  • Ms.Crystal
    sales
    Tel: +86-371-56618766

  • Ms.grace
    Tel:  +86-371-56618766

  • Ms.jessie
    Tel: Tel:+8613838303119

  • Ms.windy
    Tel: +86-371-86658258

  • Ms.judy
    Tel: 18530861832

  • Ms.Selina
    Tel: +86-371-67584905-613

  • Ms.amy
    Tel: +86-371-67584905-615

  • Ms.Summer
    Tel: +86-18239957278

  • Ms.Flora
    Tel: 0371-67584905

  • Ms.Lisa
    Tel: +86-0371-86658258

  • Ms.gena
    Tel: 18237319255

  • Mobile:
  • Tel:+86-371-86658258
  • Fax:+86-371-86652073
  • URL:http://www.coreychem.com
  • Province/state:Henan
  • City:Zhengzhou
  • Street:Building 10 of Innovation Park, East District of the National University Science Park
  • MaxCard:
Home > Products >  High quality Daptomycin(103060-53-3)factory

High quality Daptomycin(103060-53-3)factory CAS NO.103060-53-3

  • Min.Order: 1 Gram
  • Payment Terms: T/T,Western Union,Other
  • Product Details

Keywords

  • Hot sale Daptomycin
  • High quality Low price CAS NO:103060-53-3
  • 98%;in stock ,fast delivery

Quick Details

  • ProName: High quality Daptomycin(103060-53-3)fa...
  • CasNo: 103060-53-3
  • Molecular Formula: C72H101N17O26
  • Appearance: colorless to faint yellow powder
  • Application: API - antibiotic drugs
  • DeliveryTime: 2-3day
  • PackAge: According to customer requirements
  • Port: Shanghai
  • ProductionCapacity: 500 Kilogram/Week
  • Purity: 98%
  • Storage: Store at -20°C
  • Transportation: Air freight/shipping
  • LimitNum: 1 Gram

Superiority

Coreychem is a chemical company. We aim to offer high products in low price. We have ten years of professional experience in this field. We have own professional team, so do not worry. We are high efficient. Our specialization, your Confidence ! We keep committing to meet the needs of both market and customers with our innovative technology, high stable quality products and excellent service. We always combine economic success with high sense of social responsibility and environmental protection. To meet the needs of customers, to enrich the value of all TNJ staff, to shoulder more and more social responsibility...these are our unremitting pursuit. We believe and are to make true Better Chemicals, Better Future!

We could give you: 
1. Best quality with low price in your requirement 
2. Competitive price in China market 
3. experience for ten years
3. Mature Technical support 
4. Professional team and logistic support

 

Details

Product Name: Daptomycin
Synonyms: daptomycin;CUBICIN DAPTOMYCIN;Cidecin;Cubicin;Ly-146032;N-(N-Decanoyl-L-Trp-D-Asn-L-Asp-)cyclo[L-Thr*-Gly-L-Orn-L-Asp-D-Ala-L-Asp-Gly-D-Ser-[(3R)-3-methyl-L-Glu-]-3-(2-aminobenzoyl)-L-Ala-];N-[N-(1-Oxodecyl)-L-Trp-D-Asn-L-Asp-]-cyclo[L-Thr*-Gly-L-Orn-L-Asp-D-Ala-L-Asp-Gly-D-Ser-[(3R)-3-methyl-L-Glu-]-4-(2-aminophenyl)-4-oxo-L-Abu-];N-[N-Decanoyl-L-Trp-D-Asn-L-Asp-]-cyclo[Thr*-Gly-L-Orn-L-Asp-D-Ala-L-Asp-Gly-D-Ser-[(3R)-3-methyl-L-Glu-]-3-(2-aminobenzoyl)-L-Ala-]
CAS: 103060-53-3
MF: C72H101N17O26
MW: 1620.68
EINECS: 600-389-2
Product Categories: -;Antibacterial;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API;VIREAD;Inhibitors
Mol File: 103060-53-3.mol
Daptomycin Structure
 
Daptomycin Chemical Properties
Melting point  202-204 C
Fp  87℃
storage temp.  Store at -20°C
solubility  methanol: soluble5mg/mL
form  powder
color  colorless to faint yellow
λmax 260nm(EtOH)(lit.)
Merck  14,2823
InChIKey DOAKLVKFURWEDJ-RWDRXURGSA-N
 
Safety Information
WGK Germany  3
RTECS  HB5626000
HS Code  29419090
Toxicity LD50 i.v. in mice: 600 mg/kg (Debono)
MSDS Information
 
 
Daptomycin Usage And Synthesis
Antibiotic Daptomycin is a kind of cyclic lipopeptide antibiotics with novel structure. It is extracted from the Streptomyces fermentation broth. It was discovered by Eli Lilly Company in the 1980s, and successfully developed in 1997 by Cubist Pharmaceuticals. It not only having a novel chemical structure but also has mode of action which is different from any antibiotic approved before: it inhibits cell by disrupting the transport of amino acids through cell membrane, thereby blocking the cell wall peptidoglycan biosynthesis and changing the nature of the cell membrane. It can destroy the bacterial cell membrane function in many aspects, and quickly kill gram-positive bacteria. In addition to the role of taking effect on most clinically relevant gram-positive bacteria, more importantly, Daptomycin has a potent efficacy in treating isolated strains which have shown signs of resistance to methicillin, vancomycin and linezolid. This property is of great clinical significance to patients suffering from severe infection.
In September 2003, the US Food and Drug Administration had approved for the first time that daptomycin could be applied for the treatment of severe skin infections. In March 2006, it was approved for treating infectious diseases.
In January 2006, it is approved by European Commission for the treatment of certain complicated skin and soft tissue infections caused by gram-positive bacteria.
On September 6, 2007, Cubist Pharmaceuticals announced that the European Union has approved its antibacterial drug, Cubicin for the treatment of right heart endocarditis caused by Staphylococcus aureus infections and complicated skin and soft tissue infection related diseases caused by Staphylococcus aureus.
On July 29, 2010, the US Food and Drug Administration (FDA) released information on the issue that intravenous injection of daptomycin (daptomycin, produced by Cubist Pharmaceuticals, with brand name “Cubicin”) may cause eosinophilic pneumonia in order to remind the patients and medical professionals. Eosinophilic pneumonia is a rare and very severe disease whose symptoms include fever, cough, shortness of breath and difficulty in breathing.
Antibacterial effect Studies have shown that daptomycin has a similar antibacterial spectrum antibacterial with vancomycin which mainly has a strong inhibitory effect against Gram-positive bacteria, MIC of Staphylococcus spp: 0.125~0.5 μg/ml; MIC for gram bacterial spp: 0.06~0.5μg/ml; MIC for enterococci: 0.25~2.0 μg/ml. Daptomycin also has a broad antibacterial spectrum against Gram-positive anaerobic bacteria: MIC for Peptostreptococcus spp: 0.12μg/ml; MIC for Clostridium spp.: 0.5 μg/ml; MIC for Lactobacillus spp.: 1 μg/ml.
Daptomycin has a good antibacterial activity on a variety of antibiotic-resistant bacteria, for example, the MIC for methicillin-resistant carbamoyl Staphylococcus (MRSA) is 0.06~0.5 μg /mL; MIC for methicillin-resistant Staphylococcus is 0.0625~1 μg/ml; MIC for oxacillin resistant strains of Staphylococcus is 0.12~0.5 μg/ml; MIC for highly aminoglycosides-resistant enterococci is 2.5μg/mL, MIC for GmrBIa-enterococci is 0.5~1 μg/mL; MIC for glycopeptide antibiotic-resistant enterococci is 1~2 μg /mL.
Toxicology According to the information of Eli Lilly pharmaceutical laboratories, daptomycin is a relatively safe, low toxic antibiotic. LD 50 of Mouse is 142~159 mg/kg (Dog 200 mg/kg). It is non-lethal but can cause weight loss and loss of appetite; LD 50 of Monkey is 25~200 mg/kg. The main symptoms are lethargy, muscle weakness, ataxia, increase in creatinine phosphokinas, and slight irritation after skin and eye contact. With different dosage (25~125 mg/kg) of drugs being administrated (intravenously) to mice for a month, each dose group all exhibited the degeneration of both renal cortical tubular epidermis and skeletal muscle. It was also observed that sciatic nerve degeneration occurred at the dose group of 150 mg/kg dos. But It has no effect on fertility and also has no teratogenic effects. During six months of chronic toxicity test, the dog was intravenously injected with daptomycin at doses of 2, 10, 40 mg/(kg·d), respectively. Only the dogs at 40 mg /(kg·d) dose group exhibited a loss of knee jerk reaction and moderate degeneration of axonal and mild declining nerve transmission rate. But these functions can be recovered after the withdrawal for two weeks. A single around of dose at 2.0mg/kg has no effect on human muscles and nervous system.
Pharmacokinetics Healthy volunteers were administrated (intravenous injection) of six different doses in the range of 0.5~6.0 mg/kg and 1.0 mg/kg 14C marked daptomycin, the results showed that daptomycin has a relatively long T1/2 in vivo (T1/2 = 6~8 h), a relatively small volume of distribution (V = 0.1~0.2 L/kg), and a renal clearance CLr of 0.17~0.2 ml/(min kg). Daptomycin is mainly presented in the blood in the form of non-metabolized original drug with kidney as the major metabolic organ. About 78% of daptomycin is excreted in the urine. There are metabolites of daptomycin presented in the urine. The distribution pattern of daptomycin in the body is not fully understood. Patients of septicemia and endocarditis needs to subject to intravenous administration of daptomycin at a dose of 3mg/kg in every 12 h. Compared with healthy volunteers, people in daptomycin group had a average peak blood concentration (cmax): 35.45, which is lower than in healthy people. They also had an increased steady-state volume of distribution (Vss = 0.21) and a 22% increased clearance rate (CL).
In vivo activity and clinical application This product is mainly used in the treatment of endocarditis, sepsis, peritonitis and urinary tract infections caused by Staphylococcus, Streptococcus, and Enterococcus. It is of particular importance in the treatment of endocarditis caused by various drug-resistant strains. Animal experiments showed that the application of daptomycin in treatment of endocarditis, peritonitis, pneumonia, and osteomyelitis caused by MRSA or other resistant strains caused by, yields a equivalent or even better effect than vancomycin. Moreover, daptomycin has a longer in vivo t1/2 long and has a smaller side effect and therefore it has considerable clinical value. In October 1990, it was reported about the first case of the failure of daptomycin in treatment of S. aureus-caused endocarditis which is likely due to the high affinity of daptomycin to the proteins (90%), the low dose of applied drug and different pharmacokinetic parameters of patients with healthy people. Deepened study of the pharmacology and clinical application of daptomycin is still ongoing.
Resistance The incidence of the occurrence of daptomycin-resistant strains is low with only a mild resistance. In the in vitro selection of daptomycin-resistant strains from Streptococcus pneumoniae, Enterococcus, Staphylococcus, the incidence of drug-resistant strains of Streptococcus pneumoniae was the highest with 1.2 × 10-6 (16MIC) while Staphylococcus has the lowest incidence of drug-resistant strains which was only 7.0 × 10-9 (8MIC). General the MIC is only increased by 8 to 32 times. Using medium supplied no antibiotics for continuous passage of three generations can reduce the resistance ability to 1/2 to 1/4. In a rabbit model of endocarditis, after treatment of daptomycin, 13% of the rabbit produces daptomycin-resistance of Staphylococcus but with weakened resistance, indicating the stability of daptomycin resistance may involve multiple point mutations.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
Drug Interactions Daptomycin has synergistic effect when used in combination with netilmicin, amikacin, imipenem, and fosfomycin. This can improve the antibacterial activity. Combination with teicoplanin, vancomycin has a good antibacterial activity against Sma GmrBla-enterococci. Combination of daptomycin with gentamicin also has synergistic effects on resistant glycopeptide antibiotics-resistant Streptococcus faecalis. This has been demonstrated in animal models. Combination of daptomycin and tobramycin for therapy can reduce the nephrotoxicity of the latter drug, which is just opposite with vancomycin.
Uses Pharmaceutical intermediates, used in the treatment of concurrent skin and skin structure infections caused by a number of Gram-positive caused by susceptible strains.
Description Daptomycin is the first entry of a new class of cyclic lipopeptide antibiotics that disrupts multiple aspects of bacterial membrane function including disruption of membrane potential and amino acid transport, inhibition of lipoteichoic acid synthesis and inhibition of peptidoglycan synthesis. It is indicated for the treatment of complicated skin and skinstructure infections (cSSSI) caused by a range of Gram-positive bacteria. This is distinct from previous classes of antibiotics that inhibit bacterial cell wall biosynthesis, bacterial DNA replication, and folate coenzyme biosynthesis. Due to this unique mechanism, cross-resistance has not been noted with any other class of antibiotics. It is produced by the fermentation of Streptomyces roseporus. The fatty acid side chain is a key determinant of acute toxicity, with the ten-carbon chain least acutely toxic to mice. Daptomycin has shown efficacy in a variety of animal models versus several Grampositive infectious agents including methicillin-susceptible S aureus, vancomycinresistant E faecalis, spyogenes and S pneumoniae. It retains in vitro activity against methicillin, vancomycin and linezolid-resistant strains including Staphylococcus aureus (MRSA and VRSA), which is the leading cause of hospital-acquired infections (nosocomial infections (Nis)). The MIC values against Gram-positive pathogens are relatively low, ranging from 0.06 to 2.0 mg/mL. In two clinical studies treating patients (ca. 1090 for both arms of both studies) with complicated skin and soft tissue infections (cSSTIs) in which gram-positive pathogens were suspected and parenteral antibiotics were required, daptomycin provided similar clinical success rates as compared to standard therapy with vancomycin or semisynthetic penicillins such as cloxacillin, oxacillin, or flucloxacillin. The daptomycin treated group showed more rapid improvement as noted by scoring on day three or four and also had a shorter duration of treatment versus the standard therapy group (7 vs 8 days). It is dosed once daily (4 mg/kg/day) by intravenous infusion and has a half-life of 8.1 h. It is primarily cleared renally and thus requires dosing adjustments for those with severe renal insufficiency (CLCR ,30 mL/min). Clinical safety of daptomycin is similar to other antibiotics.
Chemical Properties Off-White to Light Yellow Solid
Originator Lilly (US)
Uses Cyclic lipopeptide antibiotic derived from a fermentation product of Streptomyces roseosporus; disrupts plasma membrane function in gram-positive bacteria. Antibacterial.
Uses antiviral, RT inhibitor
Uses Daptomycin is a member of the A 21978 complex of high molecular weight cyclic lipopeptides with potent antibiotic activity, notably against MRSA, VISA and VRSA bacterial strains. Originally isolated from Streptomyces roseosprous by Eli Lily in the 1980s, daptomycin was selected and developed by Cubist Pharmaceticals for human use. Daptomycin exhibits Ca-dependent depolarisation of the bacterial membrane resulting in loss of membrane potential leading to inhibition of DNA, RNA and protein synthesis which results in cell death.
Uses immunosuppressant
Uses Daptomycin is a member of the A 21978 complex of high molecular weight cyclic lipopeptides with potent antibiotic activity, notably against MRSA, VISA and VRSA bacterial strains. Originally isolated from Streptomyces roseosprous by Eli Lily in the 1980s, daptomycin was selected and developed by Cubist Pharmaceuticals for human use. Daptomycin exhibits Ca-dependent depolarisation of the bacterial membrane resulting in loss of membrane potential leading to inhibition of DNA, RNA and protein synthesis which results in cell death.
Definition ChEBI: A polypeptide comprising N-decanoyltryptophan, asparagine, aspartic acid, threonine, glycine, ornithine, aspartic acid, D-alanine, aspartic acid, glycine, D-serine, threo-3-methylglutamic ac d and 3-anthraniloylalanine (also known as kynurinine) coupled in sequence and lactonised by condensation of the carboxylic acid group of the 3-anthraniloylalanine with the alcohol group of the threonine residue.
 

Henan CoreyChem Co., Ltd, is a high-tech joint-stock enterprise specializing in high-end customized chemicals.。CoreyChem facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.

 Our R&D center building area is 811 square meters, with 3 contributing proffesor of technical advisor, 4 Dr., 10 masters, and 28 research staff. Our level of chemical synthesis is known to the industry. So we have accumulated rich experience in synthetic methods design and exploring the synthesis of new technology. Not only we are good in heterocyclic chemistry, chiral chemistry (asymmetric synthesis and enzyme reactions), metal organic synthesis, high throughput chemistry, also specializes in bioorganic chemistry, including nucleosides, nucleotides, sugar chemistry, peptide chemistry. R & D center has many sets of 10 liters, 20 liters, 50 liters, 100L multifunction high and low pressure reaction still, rotary evaporator, anhydrous anaerobic reaction devices, hydrogenation equipment, cryogenic process (-120 degrees) equipment, to complete mg level custom synthesis and kg level process development experiments. The Existing 600M NMR, LCMS, Fourier Infrared Spectrometer, liquid chromatography, differentialscanning calorimetry, and other advanced detection equipment areto ensure quality and efficient completion of R&D projects. So far our completed custom synthesis products is more than 5300 species, where dozens of them are non-CAS declaration products, almost including all types of organic reactions.

 Henan Coreychem co., LTD. is committed to provide cost effective chemical service to the global fine chemical industry product development agencies; we adhering to the consistent good commercial reputation, to create a highly efficient, high quality of chemical research, development, production, sales and service of integrated platform, let our customers faster, better get ideal and thoughtful service.

Other products of this supplier

lookchemhot product CAS New CAS